FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma
- PMID: 38824477
- DOI: 10.1007/s10495-024-01982-1
FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma
Abstract
The upregulation of programmed death ligand 1 (PD-L1) plays a crucial role in facilitating cancer cells to evade immune surveillance through immunosuppression. However, the precise regulatory mechanisms of PD-L1 in hepatocellular carcinoma (HCC) remain undefined. The correlation between PD-L1 and ubiquitin-like molecules (UBLs) was studied using sequencing data from 20 HCC patients in our center, combined with TCGA data. Specifically, the association between FAT10 and PD-L1 was further validated at both the protein and mRNA levels in HCC tissues from our center. Subsequently, the effect of FAT10 on tumor progression and immune suppression was examined through both in vivo and in vitro experiments. Utilizing sequencing data, qPCR, and Western blotting assays, we confirmed that FAT10 was highly expressed in HCC tissues and positively correlated with PD-L1 expression. Additionally, in vitro experiments demonstrated that the overexpression of FAT10 fostered the proliferation, migration, and invasion of HCC cells. Furthermore, the overexpression of FAT10 in HCC cells led to an increase in PD-L1 expression, resulting in the inhibition of T cell proliferation and the enhancement of HCC cell resistance to T cell-mediated cytotoxicity. Moreover, in vivo experiments utilizing the C57BL/6 mouse model revealed that overexpression of FAT10 effectively suppressed the infiltration of CD8 + GZMB + and CD8 + Ki67 + T cells, as well as reduced serum levels of TNF-α and IFN-γ. Mechanistically, we further identified that FAT10 upregulates PD-L1 expression via activating the PI3K/AKT/mTOR pathway, but not in a ubiquitin-like modification. In conclusion, our findings indicate that FAT10 promotes immune evasion of HCC via upregulating PD-L1 expression, suggesting its potential as a novel target to enhance the efficiency of immunotherapy in HCC.
Keywords: FAT10; Hepatocellular carcinoma; Immunosuppression; PI3K/AKT/mTOR signaling pathway; Programmed cell death ligand 1.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.Mol Med. 2025 Feb 3;31(1):38. doi: 10.1186/s10020-025-01088-7. Mol Med. 2025. PMID: 39901136 Free PMC article.
-
Cancer-associated fibroblasts-derived exosomal ZNF250 promotes the proliferation, migration, invasion, and immune escape of hepatocellular carcinoma cells by transcriptionally activating PD-L1.J Biochem Mol Toxicol. 2024 Sep;38(9):e23778. doi: 10.1002/jbt.23778. J Biochem Mol Toxicol. 2024. PMID: 39252517
-
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31. Gastroenterology. 2020. PMID: 31678303
-
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.Biomolecules. 2024 Dec 11;14(12):1581. doi: 10.3390/biom14121581. Biomolecules. 2024. PMID: 39766289 Free PMC article. Review.
-
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).Int J Mol Sci. 2021 Nov 14;22(22):12297. doi: 10.3390/ijms222212297. Int J Mol Sci. 2021. PMID: 34830179 Free PMC article.
Cited by
-
Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway.Apoptosis. 2025 Feb;30(1-2):185-196. doi: 10.1007/s10495-024-02028-2. Epub 2024 Nov 10. Apoptosis. 2025. PMID: 39522105
-
HOXB4/METTL7B cascade mediates malignant phenotypes of hepatocellular carcinoma through TKT m6A modification.Biol Direct. 2025 Mar 5;20(1):26. doi: 10.1186/s13062-025-00620-3. Biol Direct. 2025. PMID: 40045399 Free PMC article.
-
Phosphorylated FAT10 Is More Efficiently Conjugated to Substrates, Does Not Bind to NUB1L, and Does Not Alter Degradation by the Proteasome.Biomedicines. 2024 Dec 9;12(12):2795. doi: 10.3390/biomedicines12122795. Biomedicines. 2024. PMID: 39767703 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. https://doi.org/10.3322/caac.21660
-
- Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125:3384–3391. https://doi.org/10.1172/jci80011 - DOI - PubMed - PMC
-
- Schildberg F, Klein S, Freeman G, Sharpe A (2016) Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44:955–972. https://doi.org/10.1016/j.immuni.2016.05.002 - DOI - PubMed - PMC
-
- Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J et al (2020) Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 21:571–580. https://doi.org/10.1016/S1470-2045(20)30011-5 - DOI - PubMed
-
- Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y et al (2016) Pembrolizumab versus Docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London England) 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 82103221/National Natural Science Foundation of China
- 82072714/National Natural Science Foundation of China
- 81972263/National Natural Science Foundation of China
- 2020M683094/China Postdoctoral Science Foundation
- 2020B1111170004/the program of Guangdong Provincial Clinical Research Center for Digestive Diseases
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous